Preparing For Your Colonoscopy
The Colon

The colon, also called the large intestine or bowel, is the final 6-foot long segment of the digestive tract where waste is formed into solid stool. The job of the colon is to complete the digestive process and prepare waste for elimination from the body.

After you swallow food, it travels from the mouth through the esophagus to the stomach. Once broken down, the food moves from the stomach to the small intestine. The small intestine takes the nutrients from food, and the remaining indigestible portion moves into the colon. The colon stores this waste until the next bowel movement removes it from the body.

The colon is difficult to examine because of its shape and location in the body. But, when the colon needs to be examined, the best way for a doctor to do so is by colonoscopy.

What is a Colonoscopy?

A colonoscopy is a routine procedure doctors use to examine the colon. This procedure is the best way for a doctor to be able to view the entire colon and diagnose any problems.

The procedure involves the use of a colonoscope, a long, thin, flexible instrument connected to a camera and video display monitor. Colonoscopies generally take from 15 minutes to an hour to complete and are relatively safe and pain free. If the physician notices anything of concern during your colonoscopy, a biopsy (removing a small amount of tissue to examine) may be performed.
There are several reasons your doctor may recommend a colonoscopy, such as blood in the stool, frequent abdominal pain, or a change in bowel habits. In addition to diagnosing gastrointestinal problems, colonoscopies are also used to screen for colorectal cancer.

**Colorectal Cancer**

Colorectal cancer—cancer of the colon or rectum—is the third most frequently diagnosed cancer in the US (excluding skin cancer), but it is unique in that it is preventable with early detection. It is usually slow growing, and the first sign of potential colorectal cancer is often a precancerous polyp or lesion. Since polyps in the colon can develop into cancer, early detection and removal is essential.

Colonoscopy is the key to early detection and prevention. People without elevated risk factors should have their first colonoscopy at the age of 50 and subsequent colonoscopies every 10 years after that. Anyone with identified risk factors such as a family history of colorectal cancer should be screened earlier and more frequently. To assess your risk, speak to your physician.

**Early Detection**

Regular screenings and early detection are the most effective ways to fight colorectal cancer. Identifying and removing precancerous polyps and lesions can stop colon cancer before it starts. Even if cancer has developed, the 5-year survival rate when it is treated while still confined to the colon is over 90%.
Be Prepared

Before your colonoscopy, the colon needs to be completely emptied. When waste is left in the colon, the physician cannot see the colon properly. This could lead to a longer and potentially inaccurate exam, which may necessitate a second exam later.

To clean out your colon, you will need to complete a bowel prep prior to the procedure. The prep’s job is to quickly eliminate solid waste from the digestive tract—another way of saying it causes diarrhea—leaving a clean colon that your physician can examine.

You have bowel prep choices. Different bowel preps flush out the colon using different methods, so discuss your options with your physician.
• **PEG (polyethylene glycol) lavage:** 2 to 4 liters of nonabsorbable liquids that work by a “plunger effect” to push out waste matter. Certain PEG lavage regimens require use of laxatives and liquids in addition to the nonabsorbable solution.

• **Sodium phosphate solution:** 2 to 3 glasses of salt solution plus additional liquids. The solution works by drawing water into the colon and flushing out waste matter.

• **Sodium phosphate tablets:** series of tablets, taken with any clear liquid, that draws water into the colon and flushes out waste matter.

A physician’s instructions will vary depending on the type of prep prescribed, the time of the colonoscopy procedure, and specific patient characteristics. Also, most preps involve dietary restrictions a day or two before the colonoscopy.

Make sure you completely understand your physician’s instructions for the bowel prep—it is an essential part of a successful examination.
OsmoPrep™

Reliable Tolerable Tablets

OsmoPrep is a regimen of easy-to-swallow, virtually tasteless, sodium phosphate tablets taken prior to colonoscopy.

• Is a tolerable regimen with a low incidence of gastrointestinal side effects\(^2\)
• Provides exceptional colon cleansing\(^3\)
• Helps to ensure adequate hydration\(^3\)
• Has an excellent safety profile\(^2\)
• Is preferred by patients—95% of patients who took OsmoPrep would take it again for a future colonoscopy\(^2\)

The Importance of Hydration

Colon cleansing can cause dehydration, as it causes the body to lose fluids quickly. Those fluids need to be replaced. Staying hydrated before, during, and after your bowel prep is essential. Be sure to ask your doctor or nurse how to ensure appropriate hydration during your procedure.
OsmoPrep Dosing

Your physician will give you specific instructions for completing the OsmoPrep regimen consisting of a series of 5 doses of 4 tablets followed by a series of 3 doses of 4 tablets. The tablets are taken with a total of 64-oz of the clear liquid of your choice, such as

- Water
- Apple juice
- Ginger ale
- Electrolyte rehydration solution (eg, Gatorade®)
- Lemonade

First Regimen
One dose (4 tablets with 8 oz of any clear liquid) every 15 minutes for a total of 5 doses (20 tablets)

Second Regimen
One dose every 15 minutes for a total of 3 doses (12 tablets)

* Gatorade is a registered trademark of the Quaker Oats Company, Chicago, Ill.
Information about OsmoPrep

OsmoPrep is a reliable, tolerable prep, but as with all bowel preps, it may not be for you. Discuss OsmoPrep with your physician to determine whether it is an appropriate option for you.

OsmoPrep Tablets are indicated for adults 18 years of age or older who need to cleanse the colon before having a colonoscopy.

People with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, acute obstruction or pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome should exercise considerable caution before using OsmoPrep.

If you have a history of impaired renal function, acute phosphate nephropathy, seizures or are at a higher risk for seizure, are at a higher risk for cardiac arrhythmia, have known or suspected electrolyte disturbances, or take drugs that affect electrolyte levels, discuss these conditions with your physician before taking OsmoPrep. If you have electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia, speak to your physician about having your electrolytes corrected before treatment with OsmoPrep.
OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.

In clinical trials, the most commonly reported adverse reactions were temporary and self-limited abdominal bloating, nausea, abdominal pain, and vomiting.

It is recommended that patients receiving OsmoPrep Tablets adequately hydrate before, during, and after the use of OsmoPrep.

Please see accompanying full Prescribing Information for OsmoPrep.
Quick Tips Checklist

☐ Talk to your doctor; discuss different bowel prep options, and choose the one that is most likely to provide you with a safe, effective, and tolerable prep.

☐ Complete the prep; a clean colon results in the most effective colonoscopy, and your prep is more likely to be thorough if you complete the entire regimen.

☐ Follow your physician’s instructions; your physician will provide you with detailed instructions to prepare you for your colonoscopy—follow them exactly.

☐ Stay hydrated; drink at least the amount of fluid required by the prep—hydration before, during, and after the prep and colonoscopy is very important.

☐ Plan for a friend or family member to drive you home; because of the sedatives used during colonoscopy, you will not be allowed to provide your own transportation.
Definitions

**Biopsy:** small amount of tissue removed during colonoscopy for further examination.

**Bowel prep:** regimen prescribed by a physician to clean out the colon.

**Colon:** final 6-foot long segment of the digestive tract which removes solid waste from the body; also known as the large intestine or bowel.

**Colonoscope:** long, thin, flexible instrument used during colonoscopy which is connected to a camera and video display monitor.

**Colonoscopy:** procedure to examine the colon.

**Colorectal cancer:** cancer that starts in the colon or rectum.

**Hydration:** drinking liquid to restore or maintain fluid balance; an essential component of a safe, effective bowel prep.

OsmoPrep™
(sodium phosphate monobasic monohydrate, USP
and sodium phosphate dibasic anhydrous, USP Tablets
Reliable Tolerable Tablets
www.osmoprep.com
OsmoPrep™ Tablets

(sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)

DESCRIPTION

OsmoPrep (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) is a purgative used to clean the colon prior to colonoscopy. OsmoPrep is manufactured with a highly tablet binder and does not contain microcrystalline cellulose (MCC). OsmoPrep Tablets are oval, white to off-white compressed tablets, debossed with “SLX” on one side of the bisect and “102” on the other side of the bisect. Each OsmoPrep Tablet contains 1.102 grams of sodium phosphate monobasic monohydrate, USP and 0.398 grams of sodium phosphate dibasic anhydrous, USP for a total of 1.5 grams of sodium phosphate per tablet. Inert ingredients include polyethylene glycol 8000, NF; and magnesium stearate, NF. OsmoPrep is gluten-free.

The structural and molecular formulae and molecular weights of the active ingredients are shown below:

- Sodium phosphate monobasic monohydrate, USP
  Molecular Formula: NaH₂PO₄·H₂O
  Molecular Weight: 137.99

- Sodium phosphate dibasic anhydrous, USP
  Molecular Formula: Na₂HPO₄
  Molecular Weight: 141.96

OsmoPrep Tablets are for oral administration only.

CLINICAL PHARMACOLOGY

OsmoPrep Tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. The primary mode of action is thought to be through the osmotic effect of sodium, causing large amounts of water to be drawn into the colon, promoting evacuation.

Pharmacokinetics

Pharmacokinetic studies with OsmoPrep have not been conducted. However, the following pharmacokinetic study was conducted with Visicol tablets which contain the same active ingredients (sodium phosphate) as OsmoPrep. In addition, Visicol is administered at a dose that is 25% greater than the OsmoPrep dose.

An open-label pharmacokinetic study of Visicol in healthy volunteers was performed to determine the concentration-time profile of serum inorganic phosphorus levels after Visicol administration. All subjects received the approved Visicol dosing regimen (60 grams of sodium phosphate with a total liquid volume of 3.6 quarts) for colon cleansing. A 30 gram dose (20 tablets given as 3 tablets every 15 minutes with 8 ounces of clear liquids) was given beginning at 6 PM in the evening. The 30 gram dose (20 tablets given as 3 tablets every 15 minutes with 8 ounces of clear liquids) was repeated the following morning beginning at 6 AM.

Twenty-three healthy subjects (mean age 57 years old; 57% male and 43% female; and 65% Hispanic, 30% Caucasian, and 4% African-American) participated in this pharmacokinetic study. The serum phosphorus level rose from a mean (standard deviation) baseline of 4 (± 0.7) mg/dL to 7.7 (± 1.6 mg/dL) at a median of 3 hours after the administration of the first 30 gram dose of sodium phosphate tablets (see Figure 1). The serum phosphorus level rose to a mean of 6.4 (± 1.9) mg/dL, at a median of 4 hours after the administration of the second 30 gram dose of sodium phosphate tablets. The serum phosphorus level remained above baseline for a median of 24 hours after the administration of the initial dose of sodium phosphate tablets (range 16 to 48 hours).

Figure 1. Mean (±standard deviation) serum phosphorus concentrations

The upper (4.5 mg/dL) and lower (2.6 mg/dL) reference limits for serum phosphorus are represented by solid bars.

Special Populations

Renal Insufficiency: The effect of renal dysfunction on the pharmacokinetics of OsmoPrep Tablets has not been studied. Since the inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys, patients with renal disease may have difficulty excreting a large phosphate load. Thus, the following population groups compared to the Visicol group.

Geriatric: OsmoPrep Tablets should be used with caution in patients with impaired renal function (see WARNINGS). The effect of renal dysfunction on the pharmacokinetics of OsmoPrep Tablets has not been studied. Since the inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys, patients with renal disease may have difficulty excreting a large phosphate load. Thus, patients with renal insufficiency, history of — or at greater risk of — acute phosphate nephropathy, known or suspected phosphate retention states, and BUN) in patients who may be at increased risk for serious adverse events, including those with history of renal insufficiency, history of — or at greater risk of — acute phosphate nephropathy, known or suspected electrolyte disorders, sepsis, arhythmias, cardiomyopathy, prolonged QT, recent history of a MI and

In the phase 3 trial, patients were randomized into one of the following three sodium phosphate treatment groups: 1) Visicol containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with at least 3.6 quarts of clear liquids; 2) OsmoPrep containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with 2.5 quarts of clear liquids; and 3) OsmoPrep containing 60 grams of sodium phosphate (30 grams in the evening before the colonoscopy and 18 grams on the next day) with 2 quarts of clear liquids. Patients were instructed to eat a light breakfast before noon on the day prior to the colonoscopy and then were told to drink only clear liquids after noon on the day prior to the colonoscopy. The primary efficacy endpoint was the overall colon cleansing response rate in the 4-point Colonic Contents Scale. Response was defined as a rating of “excellent” or “good” on the 4-point scale as determined by the blinded colonscopist. This phase 3 study was planned to assess the non-inferiority of the two OsmoPrep groups compared to the Visicol group.

The efficacy analysis included 704 adult patients who had an elective colonoscopy. Patients ranged in age from 21 to 89 years old (mean age 56 years old with 55% female and 45% male patients. Race was distributed as follows: 87% Caucasian, 10% African-American, and 3% other race. The OsmoPrep 60 gram and 48 gram treatment groups demonstrated non-inferiority compared to Visicol. See Table 1 for the results.

Table 1: Phase 3 Study – Overall Colon Content Cleansing Response Rates

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>No. of tablets taken at 6 PM on the day prior to colonoscopy</th>
<th>No. of tablets taken the next day</th>
<th>Overall Response Rate (Excellent or Good)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OsmoPrep 32 tabs (60 g)</td>
<td>20</td>
<td>12</td>
<td>76%</td>
</tr>
<tr>
<td>OsmoPrep 40 tabs (60 g)</td>
<td>20</td>
<td>20</td>
<td>73%</td>
</tr>
<tr>
<td>Visicol</td>
<td>20</td>
<td>20</td>
<td>51%</td>
</tr>
</tbody>
</table>

*On the day of the colonoscopy, study medication was taken 3 to 5 hours before the start of the colonoscopy.

Electrolyte Changes

In the OsmoPrep clinical studies, expected serum electrolyte changes (including phosphate, calcium, potassium, and sodium) have been observed. Serum electrolyte abnormalities were not associated with any adverse events. In the OsmoPrep phase 3 trial, 96%, 96%, and 93% of patients who took 60 grams of Visicol, 60 grams of OsmoPrep, and 48 grams of OsmoPrep, respectively, developed hyperphosphatemia (defined as phosphate level > 5.1 mg/dL) on the day of the colonoscopy. In this study, patients who took 60 grams of Visicol, 60 grams of OsmoPrep, and 48 grams of OsmoPrep had baseline mean phosphate levels of 3.5, 3.5, and 3.6 mg/dL, respectively, on the day of the colonoscopy. In the OsmoPrep phase 3 study, 20%, 22%, and 18% of patients who took 60 grams of Visicol, 60 grams of OsmoPrep, and 48 grams of OsmoPrep, respectively, developed hypokalemia (defined as potassium level < 3.4 mEq/L) on the day of the colonoscopy. In this study, patients who took 60 grams of Visicol, 60 grams of OsmoPrep, and 48 grams of OsmoPrep all had baseline potassium levels of about 4.3 mEq/L and then developed a mean potassium level of 3.7 mEq/L on the day of the colonoscopy.

In the OsmoPrep phase 3 trial, several patients on all three sodium phosphate regimens demonstrated hypo- calcemia and hypomagnesemia that did not require treatment.

INDICATIONS AND USAGE

OsmoPrep Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.

CONTRAINDICATIONS

OsmoPrep Tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.

WARNINGS

Administration of sodium phosphate products prior to colonoscopy for colon cleansing has resulted in fatalities due to significant fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias. These fatalities have been observed in patients with renal insufficiency, in patients with bowel perforation, and in patients who misused or overdosed sodium phosphate products. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before, during, and after the use of OsmoPrep.

Considerable caution should be advised before OsmoPrep Tablets are used in patients with the following illnesses: severe renal insufficiency (creatinine clearance less than 30 mL/minute), congestive heart failure, ascites, unstable angina, gastric retention, ileus, acute bowel obstruction, pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric resection, or pseudo-obstruction of the bowel.

Considerable caution should be advised before OsmoPrep Tablets are used in patients with a history of renal insufficiency, history of — or at greater risk of — acute phosphate nephropathy, known or suspected electrolyte disorders, sepsis, arrhythmias, cardiomyopathy, prolonged QT, recent history of a MI and
Take 4 OsmoPrep Tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets. Patients should be instructed to drink 8 ounces of clear liquids with each 4-tablet dose of OsmoPrep Tablets. Patients should take a total of 2 quarts of clear liquids with OsmoPrep. Inadequate fluid intake, as with any other purgative, may lead to excessive fluid loss, hypovolemia, and dehydration. Dehydration from purgation may be exacerbated by inadequate oral fluid intake, vomiting, and/or use of diuretics. Patients should be instructed not to administer additional laxative or purgative agents, particularly additional sodium phosphate-based purgative or enema products. Prolongation of the QT interval has been observed in some patients who were dosed with sodium phosphate colon preparations. QT prolongation with sodium phosphate tablets has been associated with electrolyte imbalances, such as hypokalemia and hypocalcemia. OsmoPrep Tablets should be used with caution in patients who are taking medications known to prolong the QT interval, since serious complications may occur. Pre-dose and post-colonoscopy ECGs should be considered in patients with high risk of serious, cardiac arrhythmias.

PRECAUTIONS

General

Patients should be instructed to drink 8 ounces of clear liquids with each 4-tablet dose of OsmoPrep Tablets. Patients should take a total of 2 quarts of clear liquids with OsmoPrep. Inadequate fluid intake, as with any other purgative, may lead to excessive fluid loss, hypovolemia, and dehydration. Dehydration from purgation may be exacerbated by inadequate oral fluid intake, vomiting, and/or use of diuretics. Patients should be instructed not to administer additional laxative or purgative agents, particularly additional sodium phosphate-based purgative or enema products. Prolongation of the QT interval has been observed in some patients who were dosed with sodium phosphate colon preparations. QT prolongation with sodium phosphate tablets has been associated with electrolyte imbalances, such as hypokalemia and hypocalcemia. OsmoPrep Tablets should be used with caution in patients who are taking medications known to prolong the QT interval, since serious complications may occur. Pre-dose and post-colonoscopy ECGs should be considered in patients with known prolonged QT.

Administration of OsmoPrep Tablets may induce colonic mucosal aphthous ulcerations, since this endoscopic finding has been observed with other sodium phosphate cathartic preparations. In the OsmoPrep clinical program, in which aphthous ulcers were observed in 3% of patients who took the 48 gram OsmoPrep dosing regimen. This colonoscopic finding should be considered in patients with known or suspected inflammatory bowel disease. Because published data suggest that sodium phosphate absorption may be enhanced in patients experiencing an acute exacerbation of chronic inflammatory bowel disease, OsmoPrep Tablets should be used with caution in such patients.

Drug Interactions

Medications administered in close proximity to OsmoPrep Tablets may not be absorbed from the gastrointestinal tract due to the rapid intestinal peristalsis and watery diarrhea induced by the purgative agent.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of OsmoPrep. Studies to evaluate the effect of OsmoPrep on fertility or its mutagenic potential have not been performed.

Pregnancy. Teratogenic Effects: Pregnancy Category C.

Animal reproduction studies have not been conducted with OsmoPrep. It is not known whether OsmoPrep can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. OsmoPrep Tablets should be given to a pregnant woman only if clearly needed.

Pediatric Use

The safety and efficacy of OsmoPrep Tablets have not been demonstrated in patients less than 18 years of age.

Geriatric Use

In controlled colon preparation trials of OsmoPrep, 228 (24%) of 931 patients were 65 years of age or older. In addition, 49 (5%) of the 931 patients were 75 years of age or older. Of the 228 geriatric patients in the trials, 134 patients (99%) received at least 48 grams of OsmoPrep. Of the 49 patients 75 years old or older in the trials, 27 (55%) patients received at least 48 grams of OsmoPrep. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients. However, the mean phosphate levels in geriatric patients were greater than the phosphate levels in younger patients after OsmoPrep administration. The mean colonoscopy-day phosphate levels in patients 18-64, 65-74, and ≥ 75 years old who received 48 grams of OsmoPrep in the phase 3 study were 7.0, 7.3, and 8.0 mg/dL, respectively. In addition, in all three sodium phosphate treatment groups, the mean phosphate levels in patients 18-64, 65-74, and ≥ 75 years old in the phase 3 study were 7.4, 7.9, and 8.0 mg/dL, respectively, after sodium phosphate administration. Greater sensitivity of some older individuals cannot be ruled out; therefore, OsmoPrep Tablets should be used with caution in geriatric patients.

Sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. Since geriatric patients are more likely to have impaired renal function, consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and BUN) in these patients (see WARNINGS). It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before, during, and after the use of OsmoPrep.

ADVERSE REACTIONS

Abdominal bloating, abdominal pain, nausea, and vomiting were the most common adverse events reported with OsmoPrep Tablets. Dizziness and headache were reported less frequently. Since diarrhea was considered as a part of the efficacy of OsmoPrep, diarrhea was not defined as an adverse event in the clinical trials. Table 2 shows the most common adverse events with use of 48 grams of OsmoPrep, 60 grams of OsmoPrep, and 60 grams of Visicol in the colon preparation trials (n= 931).

Postmarketing Experience

In addition to adverse events reported from clinical trials, the following adverse events have been identified during post-approval use of OsmoPrep. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either their seriousness, frequency of reporting or causal connection to OsmoPrep, or a combination of these factors.

General: Hypersensitivity reactions including anaphylaxis, rash, pruritus, urticaria, throat tightness, pharyngeal edema, parathesia and swelling of the lips, and facial swelling.

Drug Abuse and Dependence

Laxatives and purgatives (including OsmoPrep) have the potential for abuse by bulimia nervosa patients who frequently have binging eating and vomiting.

OVERDOSAGE

There have been no reported cases of overdose with OsmoPrep Tablets. Purposeful or accidental ingestion of more than the recommended dosage of OsmoPrep Tablets might be expected to lead to severe electrolyte disturbances, including hypophosphatemia, hypocalcemia, hypomagnesemia, and hypokalemia, as well as dehydration and hypovolemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances resulting from overdose may lead to cardiac arrhythmias, seizure, renal failure, and death. The patient who has taken an overdose should be monitored carefully, and treated symptomatically until stable.

DOSAGE AND ADMINISTRATION

The recommended dose of OsmoPrep Tablets for colon cleansing for adult patients is 32 tablets (48 grams of sodium phosphate) taken orally with a total of 2 quarts of clear liquids every 15 minutes for a total of 12 tablets.

The evening before the colonoscopy procedure: Take 4 OsmoPrep Tablets with 8 ounces of clear liquids every 15 minutes for a total of 20 tablets.

On the day of the colonoscopy procedure: Starting 3-5 hours before the procedure, take 4 OsmoPrep Tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets.

Patients should be advised of the importance of taking the recommended fluid regimen. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before, during, and after the use of OsmoPrep.

Patients should not use OsmoPrep for colon cleansing within seven days of previous administration. No additional enema or laxative is required, and patients should be advised NOT to take additional agents, particularly those containing sodium phosphate.

HOW SUPPLIED

OsmoPrep Tablets are supplied in child-resistant bottles containing 100 tablets. Each tablet contains 1.102 g sodium phosphate monobasic monohydrate, USP and 0.398 g sodium phosphate dibasic anhydrous, USP for a total of 1.5 g of sodium phosphate per tablet. Each bottle contains two silica desiccant packets, which should not be ingested.

NDC 65649-701-41 (100 tablets)

Rx only.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature]. Discard any unused portion.

Manufactured by:

WellSpring Pharmaceutical Canada Corp.
Oakville, Ontario Canada L6H 1M5

for:

Salix Pharmaceuticals, Inc.
Grenford, N.C. 27560
Made in Canada

©2007 Salix Pharmaceuticals, Inc.
VENAR-30-1-Feb, 2007